Retatrutide has real trial data. That is not what people are buying.
The quick version
Retatrutide is a real drug in late-stage trials, with published results.
It is not approved in any country, so nobody can buy the version that was studied.
When an Australian lab tested three products sold as retatrutide, one held about half the labelled amount and one held nearly double.
Most peptides people talk about online have thin human evidence. Retatrutide is not one of them.
It has been through phase 2 and phase 3 trials. The results are published. That makes it unusual, and it makes the usual question — does the research support this? — the wrong one to ask.
The better question is simpler. The drug in those trials and the vial someone buys are not the same thing. This piece is about the distance between them.
What the trials reported
In a phase 2 obesity trial, 338 adults were randomly assigned to retatrutide or placebo for 48 weeks. It was double-blind.
The authors report average body weight change at 48 weeks of −8.7%, −17.1%, −22.8% and −24.2% across the rising dose groups. Placebo was −2.1%.
Those are large numbers, and they are the ones that travel. They get quoted in forums and videos, usually without the rest of the paper.
The rest of the paper says the most common side effects were stomach and gut problems. They were dose-related and mostly mild to moderate. The authors also record heart-rate increases that rose with dose, peaked at 24 weeks, then fell.
Nobody can buy that drug
Retatrutide is not approved anywhere. FDA names it directly, saying retatrutide and cagrilintide "are not components of FDA-approved drugs and have not been found safe and effective for any condition."
On the same page, FDA says it has warned companies selling unapproved drugs containing retatrutide and similar molecules that are "falsely labeled 'for research purposes' or 'not for human consumption.'"
That last point is worth sitting with. FDA's position is that the label on the vial does not decide what something legally is. How it is marketed does.
So the trial results are real, and the trial drug is unavailable. Whatever is being bought is something else.
What was in the vials
One group actually checked.
An Australian analysis tested three products sold as retatrutide. Each was labelled as containing 10 mg. They had been handed in anonymously to a community drug-checking service, then measured by an accredited lab.
All three did contain retatrutide. That part matched.
The amount did not.
Table view
| Product | Labelled | Measured | Share of label |
|---|---|---|---|
| 1 | 10 mg | 5.13 mg | 51.3% |
| 2 | 10 mg | 16.5 mg | 165.0% |
| 3 | 10 mg | 19.0 mg | 190.0% |
The lab also looked for heavy metals. It found no arsenic, cadmium, chromium, nickel or mercury above the limits it could measure. Lead, copper and zinc showed up at low levels the authors read as well below amounts that would raise concern.
So the problem they found was not contamination. It was arithmetic. Their conclusion: "inaccurate dosing alone may represent an important source of risk".
Three samples is three samples. The authors say so themselves. But it is the only independent measurement of this supply that we could find.
Why the mismatch matters more here
Every figure in the trial section came from material made by the sponsor to pharmaceutical standards. It was given on a fixed schedule, to screened participants, under medical supervision, with the amount in each vial known.
Change any one of those and the numbers stop describing the situation.
A vial holding 190% of its label is not a stronger version of the trial. It is an unknown quantity of a drug whose dose was carefully controlled in every study that produced the numbers people are repeating.
One documented case
There is a published case report from an acute medicine unit.
A man in his mid-30s with long-standing type 1 diabetes arrived with severe vomiting and diarrhoea, high blood sugar, ketones and acute kidney injury. He had taken a product bought online and sold as retatrutide shortly before. His partner took the same preparation and also became unwell.
His stool culture grew Shigella flexneri, a bacterial infection. The author is explicit that cause cannot be established.
It is one report, and it does not show what the product did. It shows that people are buying this, taking it, and turning up in hospital — and that when they do, nobody can say what was in the vial.
What is still unknown
Storage. There is no approved label anywhere and no pharmacopoeial standard, so no authority has set a storage condition, an in-use period, or a shelf life.
Long-term safety. The longest follow-up announced or published in the programme is 104 weeks.
Sport. USADA publishes that "GLP-1s are not prohibited in sport" and that WADA is monitoring them. That page names semaglutide, dulaglutide and exenatide — all approved drugs. It does not name retatrutide. We are not going to stretch it in either direction. Ask your own anti-doping body.
The short version
Retatrutide is not a compound short of evidence. It is a compound whose evidence describes something you cannot get.
The trials studied a known quantity of a known molecule, given on a known schedule, with a doctor watching. The market sells vials that, when three of them were measured, held between half and nearly twice what the label claimed.
Those are different subjects. Most of the conversation treats them as one.
Sources
- FDA, FDA's concerns with unapproved GLP-1 drugs used for weight loss
- Composition and labelling accuracy of products sold as retatrutide in Australia
- Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial
- Online-sourced retatrutide complicating impending diabetic ketoacidosis in a patient with type 1 diabetes
- USADA, Weight loss drugs and GLP-1s in sport